Routine administrative filing with zero trading signal. No action warranted; monitor upcoming earnings or pipeline catalysts for GSK's next material move.
GSK drugs
GSK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 18 $51.15entry
- T+1 · 3mo ago +3.38%α +3.17% · $52.88
- T+5 · 3mo ago +1.80%α +2.00% · $52.07
- T+20 · 2mo ago −1.68%α +0.06% · $50.29
- T+60 · 6d ago −1.08%α −0.08% · $50.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK filed a Form 6-K disclosing routine dividend reinvestment transactions by three PDMRs (Dr. Hal Barron, James Ford, and Maya Martinez-Davis) in their Executive Supplemental Savings Plan and 401(k) accounts. These are notional, plan-level acquisitions totaling approximately 2,489 ADSs at $49.52 each, entirely mechanical and administrative in nature, with no discretionary insider signal.
Key Facts
- Dr. Hal Barron (Non-Executive Director) acquired 2,279.563 notional ADS at $49.52 via supplemental plan dividend reinvestment.
- James Ford (SVP & Group General Counsel) acquired 53.89 notional ADS at $49.52 via supplemental plan dividend reinvestment.
- Maya Martinez-Davis (President, US) acquired 82.133 notional ADS at $49.52 via supplemental plan dividend reinvestment.
- Dr. Hal Barron also acquired 73 ADS at $49.52 via 401(k) dividend reinvestment.
- All transactions occurred on 2026-08-14 on the NYSE and are plan-driven, not open-market discretionary buys.
Financial Impact
Total notional acquisition ~$123,300 at $49.52/share, immaterial for a $100B+ market cap company.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007718 |
| Document: 0001654954-26-007718-index-headers.html | 0001654954-26-007718 |
| Document: 0001654954-26-007718-index.html | 0001654954-26-007718 |
| Document: 0001654954-26-007718.txt | 0001654954-26-007718 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers